Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 134 results for "sarabjit kour nangra"

Buy Infosys with target price of Rs 4245: Angel Broking

Sarabjit Kour Nangra of Angel Broking shares her outlook on the road ahead for Infosys. Money Control, 3 weeks ago
Infosys: How analysts read Q1 numbers MyIris, 3 weeks ago

2 images for "sarabjit kour nangra"

Business Standard India, 2 months ago
Business Standard India, 3 months ago

Nexium generic next big opportunity for Ranbaxy: Angel

Sarabjit Kour Nangra VP Research- Pharma Angel Broking W The Nexium Generic is a bigger opportunity for Ranbaxy than Valcyte generic, she says in an interview with CNBC-TV18's Ekta Batra. Given the Sun-Ranbaxy merger, Nangra sees an upside ...
 Moneycontrol.com1 month ago Launch of generic diovan key opportunities for Ranbaxy: Angel Broking  MyIris1 month ago

HCL Tech Q4 nos beat expectations; positive on stock: Angel

HCL Technologies posted numbers better than expected on OPM and net profit front, while top-line came in just in line with expectations. The company posted revenues of USD 1,407 million, up 3.4% qoq, in line with the expectation of USD 1,407.5 ...
 MyIris1 day ago

Lupin shares gain 5.5% after earnings

Shares of drug firm Lupin today rose by almost 5.5 per cent after it reported a 55.74 per cent jump in consolidated net profit for the quarter ended June 2014. Lupin's stock settled 4.90 per cent up at Rs 1,173.50 on the BSE. In intra-day session, ...
 Business Standard India2 days ago

Lupin profit rises 56 %

Buoyed by a strong performance in its U.S. and Indian operations, pharmaceutical major Lupin reported a record performance in the quarter ended June 2014 with the net profit rising 56 per cent to Rs.624.7 crore. The company reported a net sales of ...
 The Hindu2 days ago
Rediff.com

Pharma stocks could rise another 15-20%

The pharmaceutical sector has been one of the highest sectoral gainers in recent weeks, with six of the top 10 stocks by market capitalisation touching their all-time highs in July. Expectations of a strong performance in the June quarter, ahead of the results announcement by top pharma companies this week, has been one reason for the price surge. In addition, consistent performance and preference of investors for stocks in the defensive space helped the sector outshine the broader markets. ...
 Rediff.com4 days ago
[x]  

High valuations put on older generics

Mumbai, July 27: GlaxoSmithKline Plc (GSK) is likely to receive a good response if it indeed puts up its older but off-patented drugs for sale, given the massive gain Bafna Pharma made from Raricap. According to reports, Lupin is eyeing some of the ...
 Calcutta Telegraph4 days ago

IPCA Laboratories : Ratlam unit under FDA lens

Mumbai : Ipca Laboratories said it has voluntarily stopped shipments to the US from its bulk drug manufacturing facility at Ratlam, Madhya Pradesh , after the Food and Drug Administration The letter outlined a half a dozen violations of standard ...
 4 Traders6 days ago Ipca halts shipments from Ratlam unit after FDA flags violations  DNA India1 week ago After FDA concerns, Ipca halts drug shipment to US  Financial Chronicle1 week ago 'Suspension of API shipments to US will impact IPCA's FY2015 sales'  Hindu Business Line1 week ago
The Week

Wipro Q1 profit rises 29% to Rs 2,118 crore

Wipro, India's third-biggest IT services exporter, reported 29 per cent growth in June quarter profit at Rs 2,118 crore compared with Rs 1,631 crore posted for the corresponding quarter last year. Total revenue stood at Rs 11,135 crore against Rs ...
 Financial Chronicle1 week ago UPDATE 2-India's Wipro sees strong sales growth, eyes Europe deals  Reuters1 week ago Wipro sees strong sales growth, eyes Europe deals  The Week1 week ago India's Wipro sees strong sales growth, eyes Europe deals  Sharenet1 week ago
[x]  

Angel Broking maintains 'Buy' on IPCA Lab

During the recent USFDA inspection at the IPCA Labs Active Pharmaceutical Ingredients(APls) manufacturing facility situated at Ratlam (Madhya Pradesh), the company has received certain inspection observations in Form 483 from the USFDA. Consequent ...
 MyIris1 week ago Ipca stops US shipments of products from Ratlam facility  The Hindu1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sarabjit kour nangra
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less